Ascendis Pharma: TransCon CNP Orphan Designation Recommended in Europe; EC Decision Due Q4 2026
Ascendis Pharma announced that the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP) has adopted a positive opinion recommending the maintenance of orphan medicinal product designation for once-weekly TransCon CNP (navepegritide) for treating achondroplasia in children. This designation provides 10 years of market exclusivity upon final European Commission (EC) adoption. The EC's final decision on the Marketing Authorisation Application (MAA) is anticipated in Q4 2026. If approved, Ascendis plans to launch TransCon CNP, branded as YUVIWEL®, in Germany in Q1 2027. The drug was previously approved by the U.S. FDA in February 2026 for the same indication.
Key Highlights
- Ascendis Pharma's TransCon CNP (navepegritide) recommended for continued orphan medicinal product designation in Europe for achondroplasia.
- Positive opinion from EMA's Committee for Orphan Medicinal Products (COMP) follows CHMP positive opinion for marketing authorization.
- Final European Commission decision on Marketing Authorisation Application (MAA) expected in Q4 2026.
- If authorized, first EU launch of YUVIWEL® (TransCon CNP) planned for Germany in Q1 2027.
- TransCon CNP previously approved by US FDA in February 2026 for increasing linear growth in pediatric achondroplasia patients.
Price Impact
More from ASND
Ascendis Pharma: TransCon CNP Orphan Drug Designation Recommended for Maintenance in EU
Ascendis Pharma Grants 35,890 Warrants to Employees
Ascendis Pharma to Present Long-Term Data on Hypoparathyroidism and Achondroplasia Programs at ASBMR 2026